Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis

Nader Rifai, Masayuki Sakamoto, Terence Law, Vartouhi Galpchian, Neil Harris, Andrew Colin

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

High doses of ibuprofen have been shown to delay the progression of lung disease without serious adverse effects in patients with cystic fibrosis. To be effective, peak ibuprofen concentration of 50 to 100 mg/L has to be achieved. We developed an HPLC assay to rapidly determine plasma ibuprofen concentration. We used this assay to determine the pharmacokinetics of ibuprofen in patients with cystic fibrosis. The assay possessed linearity up to 500 mg/L, sensitivity to 1 mg/L, average recovery of 98%, and run-to-run precision (n = 23) of 3%. Furthermore, the assay proved to be free of interference from 51 medications. Observed time to peak concentration varied significantly between those receiving ibuprofen tablets (mean + SD, 94 ± 29 min, n = 16) and syrup (30 ± 0 min, n = 4) (P <0.0001). We conclude that the method described here is ideal for therapeutic monitoring of ibuprofen.

Original languageEnglish
Pages (from-to)1812-1816
Number of pages5
JournalClinical Chemistry
Volume42
Issue number11
StatePublished - Nov 14 1996
Externally publishedYes

Fingerprint

Pharmacokinetics
Ibuprofen
Cystic Fibrosis
Assays
High Pressure Liquid Chromatography
Pulmonary diseases
Lung Diseases
Tablets
Plasmas
Recovery
Monitoring

Keywords

  • drug monitoring
  • nonsteroidal antiinflammatory drugs

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Rifai, N., Sakamoto, M., Law, T., Galpchian, V., Harris, N., & Colin, A. (1996). Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis. Clinical Chemistry, 42(11), 1812-1816.

Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis. / Rifai, Nader; Sakamoto, Masayuki; Law, Terence; Galpchian, Vartouhi; Harris, Neil; Colin, Andrew.

In: Clinical Chemistry, Vol. 42, No. 11, 14.11.1996, p. 1812-1816.

Research output: Contribution to journalArticle

Rifai, N, Sakamoto, M, Law, T, Galpchian, V, Harris, N & Colin, A 1996, 'Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis', Clinical Chemistry, vol. 42, no. 11, pp. 1812-1816.
Rifai N, Sakamoto M, Law T, Galpchian V, Harris N, Colin A. Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis. Clinical Chemistry. 1996 Nov 14;42(11):1812-1816.
Rifai, Nader ; Sakamoto, Masayuki ; Law, Terence ; Galpchian, Vartouhi ; Harris, Neil ; Colin, Andrew. / Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis. In: Clinical Chemistry. 1996 ; Vol. 42, No. 11. pp. 1812-1816.
@article{aab80ff83dc341b296c71eaceac7ec7b,
title = "Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis",
abstract = "High doses of ibuprofen have been shown to delay the progression of lung disease without serious adverse effects in patients with cystic fibrosis. To be effective, peak ibuprofen concentration of 50 to 100 mg/L has to be achieved. We developed an HPLC assay to rapidly determine plasma ibuprofen concentration. We used this assay to determine the pharmacokinetics of ibuprofen in patients with cystic fibrosis. The assay possessed linearity up to 500 mg/L, sensitivity to 1 mg/L, average recovery of 98{\%}, and run-to-run precision (n = 23) of 3{\%}. Furthermore, the assay proved to be free of interference from 51 medications. Observed time to peak concentration varied significantly between those receiving ibuprofen tablets (mean + SD, 94 ± 29 min, n = 16) and syrup (30 ± 0 min, n = 4) (P <0.0001). We conclude that the method described here is ideal for therapeutic monitoring of ibuprofen.",
keywords = "drug monitoring, nonsteroidal antiinflammatory drugs",
author = "Nader Rifai and Masayuki Sakamoto and Terence Law and Vartouhi Galpchian and Neil Harris and Andrew Colin",
year = "1996",
month = "11",
day = "14",
language = "English",
volume = "42",
pages = "1812--1816",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "11",

}

TY - JOUR

T1 - Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis

AU - Rifai, Nader

AU - Sakamoto, Masayuki

AU - Law, Terence

AU - Galpchian, Vartouhi

AU - Harris, Neil

AU - Colin, Andrew

PY - 1996/11/14

Y1 - 1996/11/14

N2 - High doses of ibuprofen have been shown to delay the progression of lung disease without serious adverse effects in patients with cystic fibrosis. To be effective, peak ibuprofen concentration of 50 to 100 mg/L has to be achieved. We developed an HPLC assay to rapidly determine plasma ibuprofen concentration. We used this assay to determine the pharmacokinetics of ibuprofen in patients with cystic fibrosis. The assay possessed linearity up to 500 mg/L, sensitivity to 1 mg/L, average recovery of 98%, and run-to-run precision (n = 23) of 3%. Furthermore, the assay proved to be free of interference from 51 medications. Observed time to peak concentration varied significantly between those receiving ibuprofen tablets (mean + SD, 94 ± 29 min, n = 16) and syrup (30 ± 0 min, n = 4) (P <0.0001). We conclude that the method described here is ideal for therapeutic monitoring of ibuprofen.

AB - High doses of ibuprofen have been shown to delay the progression of lung disease without serious adverse effects in patients with cystic fibrosis. To be effective, peak ibuprofen concentration of 50 to 100 mg/L has to be achieved. We developed an HPLC assay to rapidly determine plasma ibuprofen concentration. We used this assay to determine the pharmacokinetics of ibuprofen in patients with cystic fibrosis. The assay possessed linearity up to 500 mg/L, sensitivity to 1 mg/L, average recovery of 98%, and run-to-run precision (n = 23) of 3%. Furthermore, the assay proved to be free of interference from 51 medications. Observed time to peak concentration varied significantly between those receiving ibuprofen tablets (mean + SD, 94 ± 29 min, n = 16) and syrup (30 ± 0 min, n = 4) (P <0.0001). We conclude that the method described here is ideal for therapeutic monitoring of ibuprofen.

KW - drug monitoring

KW - nonsteroidal antiinflammatory drugs

UR - http://www.scopus.com/inward/record.url?scp=0029828056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029828056&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 1812

EP - 1816

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 11

ER -